Compare WULF & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WULF | STAA |
|---|---|---|
| Founded | 1952 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 1.1B |
| IPO Year | 1999 | 1995 |
| Metric | WULF | STAA |
|---|---|---|
| Price | $17.34 | $20.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $20.86 | ★ $22.81 |
| AVG Volume (30 Days) | ★ 24.5M | 754.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $168,455,000.00 | ★ $239,442,000.00 |
| Revenue This Year | $126.80 | $30.82 |
| Revenue Next Year | $162.52 | $8.41 |
| P/E Ratio | ★ N/A | $80.13 |
| Revenue Growth | ★ 20.28 | N/A |
| 52 Week Low | $10.43 | $15.59 |
| 52 Week High | $29.84 | $35.87 |
| Indicator | WULF | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 30.42 |
| Support Level | $14.13 | $19.82 |
| Resistance Level | $17.76 | $20.49 |
| Average True Range (ATR) | 0.93 | 0.99 |
| MACD | 0.27 | -0.22 |
| Stochastic Oscillator | 87.89 | 2.64 |
TeraWulf Inc develops and operates large-scale digital infrastructure designed for AI and high-performance computing workloads. The Company owns and operates energy infrastructure across key U.S. power markets, providing large-scale, contiguous power capacity for next-generation compute. Its strategic sites offer direct grid connectivity and, in select locations, integrated generation, creating a foundation for scalable compute infrastructure. Built on deep expertise in energy markets and grid integration, TeraWulf approaches compute infrastructure from the foundation up- securing power, developing scalable sites, and operating with disciplined execution.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.